Teva Can Preserve $5-a-Share Earnings Goal With Mylan: Real M&A

April 17, 2015 10:43 PM

65 0

There’s no better deal for Teva Pharmaceutical Industries Ltd. right now than Mylan NV.

Teva is evaluating a purchase of $34 billion Mylan in what would be the biggest pharmaceutical acquisition so far this year. It comes after months of analysts saying Teva should consider such an acquisition to help offset the drop in revenue and profit that’s expected after generic copies of its top...

Read more

To category page